TEVA PHARM Company Profile

✉ Email this page to a colleague

TEVA PHARM has three hundred and twenty-three approved drugs.

There are thirty-four US patents protecting TEVA PHARM drugs. There are forty-four tentative approvals on TEVA PHARM drugs.

There are four hundred and fifty-eight patent family members on TEVA PHARM drugs in thirty-seven countries and nine hundred and forty-five supplementary protection certificates in eighteen countries.

International Patents:	458
US Patents:	34
Tradenames:	269
Ingredients:	261
NDAs:	323
Patent Litigation for TEVA PHARM:	See patent lawsuits for TEVA PHARM
PTAB Cases with TEVA PHARM as petitioner:	See PTAB cases with TEVA PHARM as petitioner

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-002	Jan 27, 2017		RX	Yes	No	9,216,260*PED	⤷ Sign Up			Y	⤷ Sign Up
Teva Pharms	ACYCLOVIR	acyclovir	TABLET;ORAL	075021-002	Mar 18, 1998		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Teva Pharms	CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER	ciprofloxacin	INJECTABLE;INJECTION	077138-001	Mar 18, 2008		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Pharm	ARMONAIR RESPICLICK	fluticasone propionate	POWDER;INHALATION	208798-001	Jan 27, 2017	6,748,947	⤷ Sign Up
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777-002	Feb 1, 2007	9,375,410	⤷ Sign Up
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-003	Jan 27, 2017	6,446,627	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Delayed-release Tablets	20 mg	➤ Subscribe	2015-06-03
➤ Subscribe	Injection	40 mg/mL, 1 mL pre-filled syringe	➤ Subscribe	2014-02-26
➤ Subscribe	for Injection	200 mcg/vial	➤ Subscribe	2015-05-01
➤ Subscribe	for Injection	3.5 mg/vial	➤ Subscribe	2016-10-26
➤ Subscribe	Injection	40 mg/mL, 1 mL pre-filled syringe	➤ Subscribe	2014-01-29
➤ Subscribe	for Injection	100 mcg/vial and 500 mcg/vial	➤ Subscribe	2015-04-14
➤ Subscribe	Extended-release Capsule	15 mg and 30 mg	➤ Subscribe	2008-08-11

Patent Number	Expiration Date
⤷ Sign Up	⤷ Sign Up

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0398460	SPC/GB04/032	United Kingdom	⤷ Sign Up	PRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310
1419152	122012000038	Germany	⤷ Sign Up	PRODUCT NAME: KOMBINATION AUS RILPIVIRIN ODER EINER STEREOCHEMISCH ISOMEREN FORM ODER EINEM PHARMAZEUTISCH UNBEDENKLICHEN ADDITIONSSALZ DESSELBEN, EINSCHLIESSLICH DES CHLORWASSERSTOFFSAEURESALZES VON RILPIVIRIN, UND TENOFOVIR, INSBESONDERE TENOFOVIRDISOPROXILFUMARAT.; REGISTRATION NO/DATE: EU/1/11/737/001 20111128
0454511	98C0028	Belgium	⤷ Sign Up	PRODUCT NAME: IRBESARTAN; NATL. REGISTRATION NO/DATE: EU/1/97/046/001 19970827; FIRST REGISTRATION: CH 54250 02 19970815
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.